Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 3/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17491377 | 0.88 | SMN1; SMN2 (0.48) | CYP2D6SMN1; SMN2CYP1A2PKMNPSR1 | |
| SCHEMBL28764503 | 0.84 | ALDH1A1 (0.51) | CYP2D6SMN1; SMN2CYP1A2PKMNPSR1 | |
| SCHEMBL11795879 | 0.84 | SMN1; SMN2 (0.46) | CYP2D6SMN1; SMN2CYP1A2PKMNPSR1 | |
| SCHEMBL12134271 | 0.83 | SRC (0.50) | CYP2D6SRCALDH1A1CYP3A4LMNA | |
| SCHEMBL7464800 | 0.82 | SMN1; SMN2 (0.44) | CYP2D6SMN1; SMN2CYP1A2PKMNPSR1 | |
| SCHEMBL7454241 | 0.82 | SMN1; SMN2 (0.44) | CYP2D6SMN1; SMN2CYP1A2PKMNPSR1 | |
| SCHEMBL7454235 | 0.82 | SMN1; SMN2 (0.44) | CYP2D6SMN1; SMN2CYP1A2PKMNPSR1 | |
| SCHEMBL418307 | 0.82 | ALDH1A1 (0.69) | CYP2D6SMN1; SMN2CYP1A2PKMNPSR1 | |
| SCHEMBL22355972 | 0.81 | KMT2A (0.56) | CYP2D6SMN1; SMN2CYP1A2PKMNPSR1 | |
| SCHEMBL22356140 | 0.81 | KMT2A (0.56) | CYP2D6SMN1; SMN2CYP1A2PKMNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025054244-A1 | CELLULAR DATA LIBRARY AND METHODS OF USING THE SAME | CELLARITY, INC. (US) | 2025-03-13 | — | — | WO | claimed |
| EP-2970107-B1 | PHOTOSWITCHABLE HDAC INHIBITORS | MASSACHUSETTS GEN HOSPITAL (US) | 2023-11-15 | — | — | EP | claimed |
| US-20130224211-A1 | GLYCATED CD59 PEPTIDES, THEIR PREPARATION, AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-08-29 | — | — | US | claimed |
| WO-2012027555-A2 | GLYCATED CD59 PEPTIDES, THEIR PREPARATION, AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-01 | — | — | WO | claimed |
| US-4489208-A | Process for producing D(-)mandelic acid | E.N.I. NAZIONALE IDROCARBURI (IT) | 1984-12-18 | — | — | US | claimed |
| US-20250249153-A1 | Improved Synthesis of Taurolidine, Purity Profiles and Polymorphs | CORMEDIX INC. (US) | 2025-08-07 | — | — | US | disclosed |
| WO-2025054244-A1 | CELLULAR DATA LIBRARY AND METHODS OF USING THE SAME | CELLARITY, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| EP-4507746-A1 | IMPROVED SYNTHESIS OF TAUROLIDINE, PURITY PROFILES AND POLYMORPHS | Cormedix Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| CN-118974138-A | Phosphine-borane catalyst compounds and uses thereof | 埃克森美孚化学专利公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118974137-A | Tertiary pnicogen onium-borane catalyst compounds and uses thereof | 埃克森美孚化学专利公司 | 2024-11-15 | — | — | CN | disclosed |
| US-20240075151-A1 | CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS | FISH & RICHARDSON PC | 2024-03-07 | — | — | US | disclosed |
| US-11891448-B2 | Glycated CD59 peptides, their preparation, and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-02-06 | — | — | US | disclosed |
| EP-1921917-A2 | FUSED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2008-05-21 | — | — | EP | disclosed |
| US-20080076773-A1 | Aminopiperidines as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME LLC | 2008-03-27 | — | — | US | disclosed |
| EP-1796669-A2 | AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2007024993-A2 | FUSED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2006039325-A2 | AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2006-04-13 | — | — | WO | disclosed |
| US-4489208-A | Process for producing D(-)mandelic acid | E.N.I. NAZIONALE IDROCARBURI (IT) | 1984-12-18 | — | — | US | disclosed |
| US-4332905-A | STEREOSELECTIVE ENZYMATIC HYDROLYSIS OF RACEMIC 5-SUBSTITUTED 2,4-OXAZOLIDINEDIONES | E.N.I. ENTE NOZIONALE IDROCARBURI (IT) | 1982-06-01 | — | — | US | disclosed |
| US-3998816-A | 7-[5-N-(n-Butoxyethoxy carbonyl and 2-chloroethoxy carbonyl)-amino] cephalosporins C | MEIJI SEIKA KAISHA, LTD. (JA) | 1976-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891448-B2 | Glycated CD59 peptides, their preparation, and uses thereof | CD59, SIGLEC9, CD209 | CYP2D6 4534/4885SMN1; SMN2 2623/4885CYP1A2 4744/4885 |
| US-20080076773-A1 | Aminopiperidines as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | DPP4, DPP3, DPP7 | CYP2D6 327/4885SMN1; SMN2 4325/4885CYP1A2 523/4885 |
| US-20240075151-A1 | CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS | TNF, TNFRSF1A, TNFSF11 | CYP2D6 4605/4885SMN1; SMN2 4091/4885CYP1A2 4742/4885 |
| US-20250249153-A1 | Improved Synthesis of Taurolidine, Purity Profiles and Polymorphs | MAPT, UROD, PRNP | CYP2D6 224/4885SMN1; SMN2 627/4885CYP1A2 51/4885 |
| US-20130224211-A1 | GLYCATED CD59 PEPTIDES, THEIR PREPARATION, AND USES THEREOF | CD59, SIGLEC9, CD209 | CYP2D6 4534/4885SMN1; SMN2 2623/4885CYP1A2 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.